RTP Mobile Logo
The Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer
Released November 2015

Proceedings from a CME symposium held in conjunction with the 16th World Conference on Lung Cancer. Featuring perspectives from Drs Scott N Gettinger, Jean-Charles Soria and David R Spigel. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    Lung cancer is a broad-reaching and devastating disease representing approximately 13% of all new cancer cases and 27% of all cancer deaths annually in the United States. However, the past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world.

    These video proceedings from a CME symposium held in conjunction with the 16th World Conference on Lung Cancer feature discussions with leading researchers with an expertise in the management of lung cancer regarding actual patient cases and related clinical research findings relevant to immunotherapy to address existing uncertainties and help keep clinicians up to date and informed on the current and future role of immunotherapies in the management of lung cancer.


    • Analyze the biologic basis for various immunotherapeutic strategies designed to boost an individual’s immune response to combat cancer.
    • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of immunotherapies under investigation for the treatment of lung cancer.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for patients with lung cancer.
    • Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutic agents in order to offer supportive management strategies.
    • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients with lung cancer about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Scott N Gettinger, MD
    Associate Professor of Medicine, Medical Oncology
    Yale School of Medicine
    Thoracic Oncology Program
    Developmental Therapeutics
    Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut

    No real or apparent conflicts of interest to disclose.

    Jean-Charles Soria, MD, PhD
    Full Professor, Paris University XI
    Head of Drug Development Department
    Institut Gustave Roussy
    Villejuif, France

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline, Merck, Roche Laboratories Inc, Sanofi; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi.

    David R Spigel, MD
    Program Director
    Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2015
    Expiration date: November 2016

Acknowledge and close

View video: